Sign up to access all valuation multiples
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
1988
404
LTM Revenue $289M
LTM EBITDA $16.7M
$954M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Pharming reported last 12-month revenue of $289M and EBITDA of $16.7M.
In the same period, Pharming generated $258M in LTM gross profit and -$0.6M in net income.
See Pharming valuation multiples based on analyst estimatesIn the most recent fiscal year, Pharming reported revenue of $344M and EBITDA of $18.9M.
Pharming expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pharming valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $289M | XXX | $344M | XXX | XXX | XXX |
| Gross Profit | $258M | XXX | $303M | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | 88% | XXX | XXX | XXX |
| EBITDA | $16.7M | XXX | $18.9M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| EBIT | -$0.4M | XXX | -$4.2M | XXX | XXX | XXX |
| EBIT Margin | 0% | XXX | -1% | XXX | XXX | XXX |
| Net Profit | -$0.6M | XXX | -$13.7M | XXX | XXX | XXX |
| Net Margin | 0% | XXX | -4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $31.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Pharming has current market cap of EUR 823M (or $952M), and EV of EUR 825M (or $954M).
As of October 20, 2025, Pharming's stock price is EUR 1 (or $1).
See Pharming trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $954M | $952M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialPharming's trades at 2.8x EV/Revenue multiple, and 50.6x EV/EBITDA.
See valuation multiples for Pharming and 15K+ public compsAs of October 20, 2025, Pharming has market cap of $952M and EV of $954M.
Equity research analysts estimate Pharming's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Pharming has a P/E ratio of -1399.8x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $952M | XXX | $952M | XXX | XXX | XXX |
| EV (current) | $954M | XXX | $954M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 49.3x | XXX | 50.6x | XXX | XXX | XXX |
| EV/EBIT | -1908.1x | XXX | -225.1x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1399.8x | XXX | -69.5x | XXX | XXX | XXX |
| EV/FCF | -102.0x | XXX | -318.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPharming's last 12 month revenue growth is 7%
Pharming's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.
Pharming's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Pharming's rule of X is 24% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Pharming and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 93% | XXX | 50% | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 13% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 24% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 89% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Protalix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pharming acquired XXX companies to date.
Last acquisition by Pharming was XXXXXXXX, XXXXX XXXXX XXXXXX . Pharming acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Pharming founded? | Pharming was founded in 1988. |
| Where is Pharming headquartered? | Pharming is headquartered in Netherlands. |
| How many employees does Pharming have? | As of today, Pharming has 404 employees. |
| Who is the CEO of Pharming? | Pharming's CEO is Mr. Fabrice Chouraqui, M.B.A.,Pharm.D.. |
| Is Pharming publicy listed? | Yes, Pharming is a public company listed on AMS. |
| What is the stock symbol of Pharming? | Pharming trades under PHARM ticker. |
| When did Pharming go public? | Pharming went public in 1998. |
| Who are competitors of Pharming? | Similar companies to Pharming include e.g. Julphar, Galapagos, Vivoryon Therapeutics, Armata Pharmaceuticals. |
| What is the current market cap of Pharming? | Pharming's current market cap is $952M |
| What is the current revenue of Pharming? | Pharming's last 12 months revenue is $289M. |
| What is the current revenue growth of Pharming? | Pharming revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Pharming? | Current revenue multiple of Pharming is 2.9x. |
| Is Pharming profitable? | Yes, Pharming is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Pharming? | Pharming's last 12 months EBITDA is $16.7M. |
| What is Pharming's EBITDA margin? | Pharming's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of Pharming? | Current EBITDA multiple of Pharming is 49.3x. |
| What is the current FCF of Pharming? | Pharming's last 12 months FCF is -$8.1M. |
| What is Pharming's FCF margin? | Pharming's last 12 months FCF margin is -3%. |
| What is the current EV/FCF multiple of Pharming? | Current FCF multiple of Pharming is -102.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
